Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

This study has been terminated.
(Slow accrual)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group Identifier:
First received: April 7, 2003
Last updated: February 11, 2013
Last verified: February 2013
Results First Received: January 7, 2013  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lymphoma
Interventions: Procedure: Extracorporeal Photopheresis
Drug: Pentostatin
Radiation: Total body irradiation (TBI)
Procedure: Allogeneic bone marrow transplantation
Drug: Cyclosporin (CSA)
Drug: Mycophenolate mofetil (MMF)
Drug: Methotrexate (MTX)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from ECOG member institutions between June 1, 2005 and October 10, 2007.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Transplant Reduced toxicity conditioning regimen followed by allogeneic (sibling or unrelated) transplant.

Participant Flow:   Overall Study
STARTED     6  
Death                 1  
Disease progression                 1  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Transplant Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant.

Baseline Measures
Number of Participants  
[units: participants]
[units: years]
Median ( Full Range )
  ( 21 to 60 )  
[units: participants]
Female     2  
Male     4  
Region of Enrollment  
[units: participants]
United States     6  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Participants With Successful Engraftment   [ Time Frame: Assessed daily during inpatient stay ]

2.  Secondary:   100-day Overall Survival   [ Time Frame: Assessed at least twice a week for the first 60 days and weekly until day 100. ]

3.  Secondary:   Progression-free Survival   [ Time Frame: Assessed day 100 post transplant and every 3 months during year 1, every 6 months during years 2-3, then every 12 months during years 4-5 or through diagnosis of disease progression ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Study Statistician
Organization: ECOG Statistical Office
phone: 617-632-3012

No publications provided

Responsible Party: Eastern Cooperative Oncology Group Identifier: NCT00057954     History of Changes
Other Study ID Numbers: CDR0000285659, U10CA021115, E1402
Study First Received: April 7, 2003
Results First Received: January 7, 2013
Last Updated: February 11, 2013
Health Authority: United States: Federal Government